Literature DB >> 21750470

Genotyping NAT2 with only two SNPs (rs1041983 and rs1801280) outperforms the tagging SNP rs1495741 and is equivalent to the conventional 7-SNP NAT2 genotype.

Silvia Selinski1, Meinolf Blaszkewicz, Marie-Louise Lehmann, Daniel Ovsiannikov, Oliver Moormann, Christoph Guballa, Alexander Kress, Michael C Truss, Holger Gerullis, Thomas Otto, Dimitri Barski, Günter Niegisch, Peter Albers, Sebastian Frees, Walburgis Brenner, Joachim W Thüroff, Miriam Angeli-Greaves, Thilo Seidel, Gerhard Roth, Holger Dietrich, Rainer Ebbinghaus, Hans M Prager, Hermann M Bolt, Michael Falkenstein, Anna Zimmermann, Torsten Klein, Thomas Reckwitz, Hermann C Roemer, Dietrich Löhlein, Wobbeke Weistenhöfer, Wolfgang Schöps, Syed Adibul Hassan Rizvi, Muhammad Aslam, Gergely Bánfi, Imre Romics, Michael Steffens, Arif B Ekici, Andreas Winterpacht, Katja Ickstadt, Holger Schwender, Jan G Hengstler, Klaus Golka.   

Abstract

Genotyping N-acetyltransferase 2 (NAT2) is of high relevance for individualized dosing of antituberculosis drugs and bladder cancer epidemiology. In this study we compared a recently published tagging single nucleotide polymorphism (SNP) (rs1495741) to the conventional 7-SNP genotype (G191A, C282T, T341C, C481T, G590A, A803G and G857A haplotype pairs) and systematically analysed if novel SNP combinations outperform the latter. For this purpose, we studied 3177 individuals by PCR and phenotyped 344 individuals by the caffeine test. Although the tagSNP and the 7-SNP genotype showed a high degree of correlation (R=0.933, P<0.0001) the 7-SNP genotype nevertheless outperformed the tagging SNP with respect to specificity (1.0 vs. 0.9444, P=0.0065). Considering all possible SNP combinations in a receiver operating characteristic analysis we identified a 2-SNP genotype (C282T, T341C) that outperformed the tagging SNP and was equivalent to the 7-SNP genotype. The 2-SNP genotype predicted the correct phenotype with a sensitivity of 0.8643 and a specificity of 1.0. In addition, it predicted the 7-SNP genotype with sensitivity and specificity of 0.9993 and 0.9880, respectively. The prediction of the NAT2 genotype by the 2-SNP genotype performed similar in populations of Caucasian, Venezuelan and Pakistani background. A 2-SNP genotype predicts NAT2 phenotypes with similar sensitivity and specificity as the conventional 7-SNP genotype. This procedure represents a facilitation in individualized dosing of NAT2 substrates without losing sensitivity or specificity.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21750470     DOI: 10.1097/FPC.0b013e3283493a23

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN: 1744-6872            Impact factor:   2.089


  21 in total

1.  Novel tagging SNP rs1495741 and 2-SNPs (rs1041983 and rs1801280) yield a high prediction of the NAT2 genotype in HapMap samples.

Authors:  Yi Jing He; Michael H Shapero; Howard L McLeod
Journal:  Pharmacogenet Genomics       Date:  2012-04       Impact factor: 2.089

2.  Accuracy of various human NAT2 SNP genotyping panels to infer rapid, intermediate and slow acetylator phenotypes.

Authors:  David W Hein; Mark A Doll
Journal:  Pharmacogenomics       Date:  2011-11-17       Impact factor: 2.533

3.  The differential effect of NAT2 variant alleles permits refinement in phenotype inference and identifies a very slow acetylation genotype.

Authors:  Jhon D Ruiz; Carmen Martínez; Kristin Anderson; Myron Gross; Nicholas P Lang; Elena García-Martín; José A G Agúndez
Journal:  PLoS One       Date:  2012-09-06       Impact factor: 3.240

4.  Trends in qualifying biomarkers in drug safety. Consensus of the 2011 meeting of the spanish society of clinical pharmacology.

Authors:  José A G Agúndez; Jaime Del Barrio; Teresa Padró; Camilla Stephens; Magí Farré; Raúl J Andrade; Lina Badimon; Elena García-Martín; Gemma Vilahur; M Isabel Lucena
Journal:  Front Pharmacol       Date:  2012-01-19       Impact factor: 5.810

5.  N-acetyltransferase 2 (NAT2) genotype as a risk factor for development of drug-induced liver injury relating to antituberculosis drug treatment in a mixed-ethnicity patient group.

Authors:  Ching-Soon Ng; Abul Hasnat; Abdullah Al Maruf; Maizbha Uddin Ahmed; Munir Pirmohamed; Christopher P Day; Guruprasad P Aithal; Ann K Daly
Journal:  Eur J Clin Pharmacol       Date:  2014-06-03       Impact factor: 2.953

Review 6.  Arylamine N-acetyltransferase acetylation polymorphisms: paradigm for pharmacogenomic-guided therapy- a focused review.

Authors:  David W Hein; Lori M Millner
Journal:  Expert Opin Drug Metab Toxicol       Date:  2020-11-03       Impact factor: 4.481

7.  Distinct SNP combinations confer susceptibility to urinary bladder cancer in smokers and non-smokers.

Authors:  Holger Schwender; Silvia Selinski; Meinolf Blaszkewicz; Rosemarie Marchan; Katja Ickstadt; Klaus Golka; Jan G Hengstler
Journal:  PLoS One       Date:  2012-12-20       Impact factor: 3.240

8.  Highlight report: Validation of prognostic genes in lung cancer.

Authors:  Rosemarie Marchan
Journal:  EXCLI J       Date:  2014-05-06       Impact factor: 4.068

9.  Impact of urinary bladder cancer risk variants on prognosis and survival.

Authors:  Silvia Selinski
Journal:  EXCLI J       Date:  2014-11-28       Impact factor: 4.068

10.  The post GWAS era: strategies to identify gene-gene and gene-environment interactions in urinary bladder cancer.

Authors:  Silvia Selinski
Journal:  EXCLI J       Date:  2014-11-03       Impact factor: 4.068

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.